Brief: Oncolytics Biotech announces registration pathway and clinical development plan
April 12 (Reuters) - Oncolytics Biotech Inc ONC.TO -
* Announces registration pathway and clinical development
plan
* Announced initial registration pathway and clinical
development plan for reolysin, proprietary immuno-oncology viral
agent
* Trial will recruit approximately 44 patients across up to
six myeloma UK clinical trial network centres in UK
* Oncolytics and Celgene UK & Ireland are providing
respective products for muk eleven
* Oncolytics is providing Reolysin and Celgene UK & Ireland
is providing imnovid and revlimid
Source text for Eikon: ID:nPn8k2QFsa
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer